Artículos de revistas
Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer
Fecha
2010Registro en:
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, v.28, n.6, p.624-627, 2010
1078-1439
10.1016/j.urolonc.2008.10.012
Autor
REIS, Sabrina Thalita dos
VILLANOVA, Fabiola Elizabeth
ANDRADE, Priscila Maria
PONTES JR., Jose
SOUSA-CANAVEZ, Juliana Moreira de
SANUDO, Adriana
ANTUNES, Alberto Azoubel
DALL`OGLIO, Marcos Francisco
Srougi, Miguel
LEITE, Katia Ramos Moreira
Institución
Resumen
Objective: Prostate cancer (PCa) is the most frequent tumor in males in Brazil. Single nucleotide polymorphisms (SNP) have been demonstrated in the promoter region of matrix metalloproteinases (MMPs) genes and have been associated with development and progression of some cancers. In this study, our aim was to investigate a possible relation between polymorphism of the promoter region of the MMP2 gene and classical prognostic parameters in prostate cancer. Materials and methods: Genomic DNA was extracted using conventional protocols. The DNA sequence containing the polymorphic site was amplified by real-time polymerase chain reaction, using fluorescent probes (TaqMan). Results: In patients with tumors of a higher stage (pT3), a polymorphic allele in the MMP2 gene was more frequent (P = 0.026) than in patients with lower tumor stage. A polymorphic allele in the MMP2 gene was more frequent in Gleason >= 7 than in Gleason <= 6 (P = 0.042). Conclusions: We conclude that MMP2 polymorphism can be used together with pathological stage and Gleason score to identify patients with worse prognosis. Our results illustrate the potential use of MMP2 SNP as a molecular marker for prostate cancer. (C) 2010 Elsevier Inc. All rights reserved.